HCA monthly performance report
Check HCA's monthly returns, drawdown, and seasonality trends — updated every month.
HCA monthly report
—
Key takeaways
- HCA Healthcare (HCA) closed November 2026 at $499.05, up 5.47% for the month and +5.44% over the trailing 12 months.
- Year-to-date, HCA is +6.90%, underperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading +11.95% versus its 200-day moving average ($445.77), a bullish technical signal.
- Over the past three years, HCA has outperformed the S&P 500 by +45.61%, with a relative strength index reading of 126.6.
- Win rate over the trailing 39 months stands at 64.1% — 25 positive months versus 14 negative months.
HCA Healthcare ended November 2026 at $499.05, posting a monthly return of +5.47%. The S&P 500 returned −0.18% over the same window, leaving relative performance at +5.64%.
The current quarter stands at +16.94% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +11.95% versus the 200-day moving average ($445.77).
Year-to-date, HCA is +6.90% against SPY +10.62%, a gap of −3.73%. The stock is currently −10.33% below its 52-week high, with maximum 3-year drawdown at −33.72%.
| Period | HCA | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −0.32% | −0.36% | +0.04% |
| 1 Week | +0.82% | +2.59% | −1.77% |
| 1 Month | +5.47% | −0.18% | +5.64% |
| 3 Months | +23.23% | −2.37% | +25.60% |
| 6 Months | +15.33% | +0.83% | +14.51% |
| YTD | +6.90% | +10.62% | −3.73% |
| 12 Months | +5.44% | +12.25% | −6.81% |
| 3 Years | +116.99% | +71.37% | +45.61% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2025 | +14.12% |
| #2 | Jul 2024 | +13.00% |
| #3 | Mar 2025 | +12.81% |
| #4 | Jan 2024 | +12.64% |
| #5 | Oct 2026 | +10.88% |
| Rank | Month | Return |
|---|---|---|
| #1 | May 2026 | −12.87% |
| #2 | Oct 2024 | −11.73% |
| #3 | Sep 2023 | −11.29% |
| #4 | Mar 2026 | −10.66% |
| #5 | Nov 2024 | −8.79% |
| Quarter | Return |
|---|---|
| Q3 2025 | +11.25% |
| Q4 2025 | +9.54% |
| Q1 2026 | +1.37% |
| Q2 2026 | −17.61% |
| Q3 2026 | +9.45% |
| Q4 2026 (QTD) | +16.94% |
| Year | Return |
|---|---|
| 2023 | +12.80% |
| 2024 | +10.89% |
| 2025 | +55.54% |
| 2026 | +6.90% |
| Metric | Value |
|---|---|
| 52-Week High | $556.52 (2026-03-12) |
| 52-Week Low | $354.00 (2026-07-14) |
| Current Price | $499.05 |
| 200-Day Moving Average | $445.77 |
| Price vs 200DMA | +11.95% |
| 3-Year Maximum Drawdown | −33.72% (2026-06-08) |
| Current Drawdown from 52W High | −10.33% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 126.6 |
| 3-Year Excess Return vs S&P 500 | +45.61% |
| RS Peak | 154 (Mar 2026) |
| RS Trough | 91.5 (Jun 2026) |
| Status | Outperforming Benchmark |
Frequently asked questions
What was HCA's return for this report period?
HCA returned +5.47% in the latest monthly window ending 2026-11-13.
Has HCA outperformed SPY year to date?
YTD HCA: +6.90% vs SPY: +10.62%.
What is HCA's 12-month return?
+5.44% over the trailing 12 months.
Is HCA above or below its 200-day moving average?
Price is +11.95% versus 200DMA ($445.77).
What is the maximum drawdown in the 3-year window?
−33.72% on 2026-06-08.